Assessing long-term treatment efficacy in chronic hepatitis B and C: Between evidence and common sense

Journal of Hepatology

Volumn 57, Issue 6, 2012, Pages 1326-1335

  Aghemo, Alessio ^a   Lampertico, Pietro ^a   Colombo, Massimo ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; CRYOGLOBULIN; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; TELBIVUDINE; TENOFOVIR; VIRUS RNA;

ANTIVIRAL THERAPY; ASCITES; B LYMPHOCYTE ACTIVATION; CANCER RISK; CAROTID ATHEROSCLEROSIS; CRYOGLOBULINEMIA; DECOMPENSATED LIVER CIRRHOSIS; DELTA AGENT HEPATITIS; DIABETES MELLITUS; DISEASE CONTROL; DISEASE COURSE; FATTY LIVER; GASTROSCOPY; HEPATITIS B; HEPATITIS C; HUMAN; INFECTION PREVENTION; INFECTION RISK; INSULIN RESISTANCE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER INJURY; LIVER TRANSPLANTATION; LONG TERM CARE; MONOTHERAPY; MORBIDITY; MORTALITY; NONHODGKIN LYMPHOMA; PORTAL HYPERTENSION; PRIORITY JOURNAL; REMISSION; REVIEW; RISK ASSESSMENT; SEROCONVERSION; STOMACH VARICES BLEEDING; SURVIVAL; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT RESPONSE; VIRUS DETECTION; VIRUS REPLICATION;

DISEASE PROGRESSION; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; SEROEPIDEMIOLOGIC STUDIES;

EID: 84869222183     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2012.06.025     Document Type: Review

References (91)

1. D. Thomas, and F. Zoulim New challenges in viral hepatitis Gut 61 2012 i1ei5
2. D.J. Mutimer, and A. Lok Management of HBV- and HCV-induced end stage liver disease Gut 61 2012 i59 i67
3. W. Chotiyaputta, and A. Lok Endpoints of hepatitis B treatment J Viral Hepat 17 2010 675 684
4. EASL Clinical Practice Guidelines. Management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-185.
5. EASL Clinical Practice Guidelines Management of hepatitis C virus infection J Hepatol 55 2011 245 264
6. M.G. Swain, M.Y. Lai, M.L. Shiffman, W.G. Cooksley, S. Zeuzem, and D.T. Dieterich A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin Gastroenterology 139 2010 1593 1601
7. S. Maylin, M. Martinot-Peignoux, R. Moucari, N. Boyer, M.P. Ripault, and D. Cazals-Hatem Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C Gastroenterology 135 2008 821 829
8. M. Martinot-Peignoux, C. Stern, S. Maylin, M.P. Ripault, N. Boyer, and L. Leclere Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin Hepatology 51 2010 1122 1126
9. I. Campos-Varela, L. Castells, J.I. Esteban, M. Bes, F. Rodríguez-Frías, and G. Sapisochin Twelve-week posttreatment follow-up to predict sustained virologic response for recurrent hepatitis C infection in liver recipients Transplantation 93 2012 450 453
10. A. Aghemo, M.G. Rumi, S. De Nicola, and M. Colombo Twelve-week posttreatment follow-up predicts a sustained virological response to pegylated interferon and ribavirin therapy Hepatology 52 2010 1170 1171
11. A. Rivero-Juárez, J.A. Mira, I. Pérez-Camacho, J. Macías, A. Camacho, and K. Neukam Twelve week post-treatment follow-up predicts sustained virological response to pegylated interferon and ribavirin therapy in HIV/hepatitis C virus co-infected patients J Antimicrob Chemother 66 2011 1351 1353
12. E.H. Buster, H.J. Flink, Y. Cakaloglu, K. Simon, J. Trojan, and F. Tabak Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b Gastroenterology 135 2008 459 467
13. Y.F. Liaw, M.R. Brunetto, and S. Hadziyannis The natural history of chronic HBV infection and geographical differences Antivir Ther 15 2010 25 33
14. J.D. Chen, H.I. Yang, U.H. Iloeje, S.L. You, S.N. Lu, and L.Y. Wang Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death Gastroenterology 138 2010 1747 1754
15. G. Fattovich, N. Olivari, M. Pasino, M. D'Onofrio, E. Martone, and F. Donato Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years Gut 57 2008 84 90
16. C. Niederau, T. Heintges, S. Lange, G. Goldmann, C.M. Niederau, and L. Mohr Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B N. Engl. J. Med. 334 1996 1422 1427
17. J.G. Reijnders, M.J. Perquin, N. Zhang, B.E. Hansen, and H.L. Janssen Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B Gastroenterology 139 2010 491 498
18. A.B. van Nunen, B.E. Hansen, D.J. Suh, H.F. Lohr, L. Chemello, and H. Fontaine Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pre-treatment serum hepatitis B virus DNA and alanine aminotransferase Gut 52 2003 420 424
19. B.-C. Song, D.J. Suh, H.C. Lee, Y.-H. Chung, and Y.S. Lee Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea Hepatology 32 2000 803 806
20. J.L. Dienstag, J. Cianciara, S. Karayalcin, K.V. Kowdley, B. Willems, and S. Plisek Durability of serologic response after lamivudine treatment of chronic hepatitis B Hepatology 37 2003 748 755
21. S.K. Yoon, J.W. Jang, C.W. Kim, S.H. Bae, J.Y. Choi, and S.W. Choi Long-term results of lamivudine monotherapy in Korean patients with HBeAg-positive chronic hepatitis B: response and relapse rates, and factors related to durability of HBeAg seroconversion Intervirology 48 2005 341 349
22. I.C. Wu, M.L. Shiffman, M.J. Tong, P. Marcellin, E. Mondou, and D. Lok Entecavir (ETV) monotherapy for 96 weeks is comparable to combination therapy with ETV plus tenofovir (TDF) in nucleos(t)ide naive patients with chronic hepatitis B: the BELOW study Hepatology 54 2011 471A
23. J. Liu, H.I. Yang, M.H. Lee, S.N. Lu, C.L. Jen, and L.Y. Wang Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study Gastroenterology 139 2010 474 482
24. T.C. Tseng, C.J. Liu, H.C. Yang, T.H. Su, C.C. Wang, and C.L. Chen Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load Hepatology 55 2012 68 76
25. T.C. Tseng, C.J. Liu, T.H. Su, C.C. Wang, C.L. Chen, and P.J. Chen Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters Gastroenterology 141 2011 517 525
26. B.J. McMahon, P. Holck, L. Bulkow, and M. Snowball Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus Ann Intern Med 135 2001 759 768
27. H.L. Chan, A. Thompson, M. Martinot-Peignoux, T. Piratvisuth, M. Cornberg, and M.R. Brunetto Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report J Hepatol 55 2011 1121 1131
28. M.F. Yuen, D.K. Wong, J. Fung, P. Ip, D. But, and I. Hung HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma Gastroenterology 135 2008 1192 1199
29. T. Pollicino, G. Squadrito, G. Cerenzia, I. Cacciola, G. Raffa, and A. Craxi Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection Gastroenterology 126 2004 102 110
30. T.T. Chang, Y.F. Liaw, S.S. Wu, E. Schiff, K.H. Han, and C.L. Lai Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B Hepatology 52 2010 886 893
31. P. Marcellin, M. Buti, E.J. Gane, Z. Krastev, R. Flisiak, and G. Germanidis Five years of treatment with tenofovir DF for chronic hepatitis B infection is associated with sustained viral suppression and significant regression of histological fibrosis and cirrhosis Hepatology 54 2011 1378A
32. Y.F. Liaw, J.J. Sung, W.C. Chow, G. Farrell, C.Z. Lee, and H. Yuen Lamivudine for patients with chronic hepatitis B and advanced liver disease N Engl J Med 351 2004 1521 1531
33. G.V. Papatheodoridis, P. Lampertico, S. Manolakopoulos, and A. Lok Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review J Hepatol 53 2010 348 356
34. G.V. Papatheodoridis, S. Manolakopoulos, G. Touloumi, G. Vourli, M. Raptopoulou-Gigi, and I. Vafiadis-Zoumbouli Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study Gut 60 2011 1109 1116
35. M. Kurokawa, N. Hiramatsu, T. Oze, T. Yakushijin, M. Miyazaki, and A. Hosui Long-term effect of lamivudine treatment on the incidence of hepatocellular carcinoma in patients with hepatitis B virus infection J Gastroenterol 47 2012 577 585
36. P. Lampertico, M. Vigano, and R. Soffredini Entecavir monotherapy for nuc-naive chronic hepatitis B patients from field practice: high efficacy and favorable safety profile over 3 years Hepatology 54 2011 1043A Abstract 1436
37. H. Koga, T. Ide, K. Oho, R. Kuwahara, T. Hino, and K. Ogata Lamivudine treatment-related morphological changes of esophageal varices in patients with liver cirrhosis Hepatol Res 37 2007 503 509
38. M. Iavarone, P. Lampertico, and M. Vigano Six years of on demand LAM + ADV combination therapy significantly reduces the development and progression of esophageal varices in patients with HBeAg-negative cirrhosis J Hepatol 46 2007 S189
39. S. Manolakopoulos, C. Triantos, J. Theodoropoulos, J. Vlachogiannakos, A. Kougioumtzan, and G. Papatheodoridis Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertension J Hepatol 51 2009 468 474
40. G. Fattovich, M. Pantalena, I. Zagni, G. Realdi, S.W. Schalm, and E. Christensen Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients Am J Gastroenterol 97 2002 2886 2895
41. C.M. Chu, and Y.F. Liaw Hepatitis B virus-related cirrhosis: natural history and treatment Semin Liver Dis 26 2006 142 152
42. Y.F. Liaw, I.S. Sheen, C.M. Lee, U.S. Akarca, G.V. Papatheodoridis, and F. Suet-Hing Wong Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease Hepatology 53 2011 62 72
43. A.K. Singal, and R.J. Fontana Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis Aliment Pharmacol Ther 35 2012 674 689
44. M.K. Osborn, S.H. Han, A. Regev, N.H. Bzowej, M.B. Ishitani, and T.T. Tran Outcomes of patients with hepatitis B who developed antiviral resistance while on the liver transplant waiting list Clin Gastroenterol Hepatol 5 2007 1454 1461
45. F. van Bömmel, T. Wünsche, S. Mauss, P. Reinke, A. Bergk, and D. Schürmann Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection Hepatology 40 2004 1421 1425
46. European Liver Transplant Registry. http://www.eltr.org/spip.php?page= documents; 2012 [accessed 17.04.12].
47. P. Lampertico, M. Viganò, S. Bhoori, F. Agnelli, M.F. Donato, and M. Bongini Low risk of hepatocellular carcinoma recurrence after liver transplantation: a 3-year follow-up study in 78 patients with chronic hepatitis B J Hepatol 48 2008 151
48. P. Lampertico, and Y.F. Liaw New perspectives in the therapy of chronic hepatitis B Gut 61 2012 i18 i24
49. L.H. Omland, H. Krarup, P. Jepsen, J. Georgsen, L.H. Harritshoj, and K. Riisom Mortality in patients with chronic and cleared hepatitis C viral infection: a nationwide cohort study J Hepatol 53 2010 36 42
50. J. Amin, M.G. Law, M. Bartlett, J.M. Kaldor, and G.J. Dore Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study Lancet 368 2006 938 945
51. M. Levrero Viral hepatitis and liver cancer: the case of hepatitis C Oncogene 25 2006 3834 3847
52. L.I. Backus, D.B. Boothroyd, B.R. Phillips, P. Belperio, J. Halloran, and L.A. Mole A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C Clin Gastroenterol Hepatol 9 2011 509 516
53. B.L. Pearlman, and N. Traub Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more Clin Infect Dis 52 2011 889 900
54. A.L. Zignego, C. Ferri, S.A. Pileri, P. Caini, and F.B. Bianchi Extrahepatic manifestations of hepatitis C virus infection: a general overview and guidelines for a clinical approach Dig Liver Dis 39 2007 2 17
55. D. Saadoun, T. Asselah, M. Resche-Rigon, F. Charlotte, P. Bedossa, and D. Valla Cryoglobulinemia is associated with steatosis and fibrosis in chronic hepatitis C Hepatology 43 2006 1337 1345
56. T. Asselah, L. Rubbia-Brandt, P. Marcellin, and F. Negro Steatosis in chronic hepatitis C: why does it really matter? Gut 55 2006 123 130
57. R. Moucari, T. Asselah, D. Cazals-Hatem, H. Voitot, N. Boyer, and M.P. Ripault Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis Gastroenterology 134 2008 416 423
58. E. Bugianesi, F. Salamone, and F. Negro The interaction of metabolic factors with HCV infection: does it matter? J Hepatol 56 2012 S56 S65
59. D.L. White, V. Ratziu, and H.B. El-Serag Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis J Hepatol 49 2008 831 844
60. S. Petta, D. Torres, G. Fazio, C. Cammà, D. Cabibi, and V. Di Marco Carotid atherosclerosis and chronic hepatitis C: a prospective study of risk associations Hepatology 55 2012 1317 1323
61. N. Perico, D. Cattaneo, B. Bikbov, and G. Remuzzi Hepatitis C infection and chronic renal diseases Clin J Am Soc Nephrol 4 2009 207 220
62. D.M. Forton, and C. Hepatitis Treatment - clearing the mind J Hepatol 56 2012 513 514
63. Y. Kasama, S. Sekiguchi, M. Saito, K. Tanaka, M. Satoh, and K. Kuwahara Persistent expression of the full genome of hepatitis C virus in B cells induces spontaneous development of B-cell lymphomas in vivo Blood 116 2010 4926 4933
64. Y. Arase, F. Suzuki, Y. Suzuki, N. Akuta, M. Kobayashi, and Y. Kawamura Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C Hepatology 49 2009 739 744
65. Y. Kawamura, K. Ikeda, Y. Arase, H. Yatsuji, H. Sezaki, and T. Hosaka Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C Am J Med 120 2007 1034 1041
66. V. Byrnes, A. Miller, D. Lowry, E. Hill, C. Weinstein, and D. Alsop Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition J Hepatol 56 2012 549 556
67. A. Aghemo, G.M. Prati, M.G. Rumi, R. Soffredini, R. D'Ambrosio, and E. Orsi A sustained virological response prevents development of insulin resistance in chronic hepatitis C patients Hepatology 2012 10.1002/hep.25867
68. A. Sangiovanni, G.M. Prati, P. Fasani, G. Ronchi, R. Romeo, and M. Manini The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients Hepatology 43 2006 1303 1310
69. H. Yoshida, J. Arakawa, M. Sata, S. Nishiguchi, M. Yano, and S. Fujiyama Interferon therapy prolonged life expectancy among chronic hepatitis C patients Gastroenterology 123 2002 483 491
70. G. Fattovich, G. Giustina, and F. Degos Effectiveness of interferon-alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C J Hepatol 27 1997 201 205
71. M.L. Yu, S.M. Lin, W.L. Chuang, C.Y. Dai, J.H. Wang, and S.N. Lu A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide multicenter study in Taiwan Antivir Ther 11 2006 985 994
72. H. Yoshida, Y. Shiratori, M. Moriyama, Y. Arakawa, T. Ide, and M. Sata Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan Ann Intern Med 131 1999 174 181
73. Y. Shiratori, Y. Ito, O. Yokosuka, F. Imazeki, R. Nakata, and N. Tanaka Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival Ann Intern Med 142 2005 105 114
74. S. Bruno, T. Stroffolini, M. Colombo, S. Bollani, L. Benvegnu, and G. Mazzella Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study Hepatology 45 2007 579 587
75. B.J. Veldt, E.J. Heathcote, H. Wedemeyer, J. Reichen, W.P. Hofmann, and S. Zeuzem Sustained virological response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis Ann Intern Med 147 2007 677 684
76. A.C. Cardoso, R. Moucari, C. Figueiredo-Mendes, M.P. Ripault, N. Giuily, and C. Castelnau Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis J Hepatol 52 2010 652 657
77. S. Bruno, A. Crosignani, C. Facciotto, S. Rossi, L. Roffi, and A. Redaelli Sustained virological response prevents the development of esophageal varices in compensated Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study Hepatology 51 2010 2069 2076
78. R. D'Ambrosio, A. Aghemo, M.G. Rumi, M. Primignani, A. Dell'Era, and P. Lampertico The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy Antivir Ther 16 2011 677 684
79. V. Mallet, H. Gilgenkrantz, J. Serpaggi, V. Verkarre, A. Vallet-Pichard, and H. Fontaine Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C Ann Intern Med 149 2008 399 403
80. R. D'Ambrosio, A. Aghemo, M. Grazia Rumi, G. Ronchi, M.F. Donato, and V. Paradis A morhometrical and immunohistochemical study to assess the benefit of a SVR in HCV cirrhotic patients Hepatology 56 2012 532 543
81. A. Rubín, V. Aguilera, and M. Berenguer Liver transplantation and hepatitis C Clin Res Hepatol Gastroenterol 35 2011 805 812
82. H.B. El-Serag, J. Talwalkar, and W.R. Kim Efficacy, effectiveness, and comparative effectiveness in liver disease Hepatology 52 2010 403 407
83. J.W. Ward, A.S. Lok, D.L. Thomas, H.B. El-Serag, and W.R. Kim Report on a single-topic conference on "Chronic viral hepatitis - strategies to improve effectiveness of screening and treatment" Hepatology 55 2012 307 315
84. M.L. Volk, R. Tocco, S. Saini, and A.S. Lok Public health impact of antiviral therapy for hepatitis C in the United States Hepatology 50 2009 1750 1755
85. C. Cohen, S.D. Holmberg, B.J. McMahon, J.M. Block, C.L. Brosgart, and R.G. Gish Is chronic hepatitis B being undertreated in the United States? J Viral Hepat 18 2011 377 383
86. B. Lettmeier, N. Mühlberger, R. Schwarzer, G. Sroczynski, D. Wright, and S. Zeuzem Market uptake of new antiviral drugs for the treatment of hepatitis C J Hepatol 49 2008 528 536
87. J.R. Kramer, F. Kanwal, P. Richardson, M. Mei, and H.B. El-Serag Gaps in the achievement of effectiveness of HCV treatment in national VA practice J Hepatol 56 2012 320 325
88. A. Aghemo, and M. Colombo Interferon-free oral therapy for hepatitis C: "Faraway, so Close!" Gastroenterology 142 2012 1253 1254
89. T. Asselah, and P. Marcellin Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow Liver Int 32 2012 88 102
90. W. Chotiyaputta, C. Peterson, F.A. Ditah, D. Goodwin, and A.S. Lok Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B J Hepatol 54 2011 12 18
91. J.H. Hoofnagle, K.D. Mullen, D.B. Jones, V. Rustgi, A. Di Bisceglie, and M. Peters Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report N Engl J Med 315 1986 1575 1578